578 results
8-K
EX-99.1
TEVA
Teva- Pharmaceutical Industries Ltd.
8 May 24
Teva Reports First Quarter 2024 Financial Results and Reaffirms 2024 Financial Outlook
7:01am
of 2023, mainly due to growth in volume including the launch of AUSTEDO XR in May 2023, as well as expanded access for patients and increased investment
DEFA14A
TEVA
Teva- Pharmaceutical Industries Ltd.
16 Apr 24
Additional proxy soliciting materials
4:16pm
to you on the Internet. We encourage you to access and review all of the important information contained in the proxy materials before voting … Access — View your proxy materials and vote. Step 1: Go to www.investorvote.com/teva. Step 2: Click on the icon on the right to view meeting materials
SD
EX-1.01
ejv0jgsed pb3
24 May 23
Conflict minerals disclosure
12:00am
DEFA14A
dbgda1fe l9
19 Apr 23
Additional proxy soliciting materials
4:12pm
8-K
EX-99.1
n6s6ydelub1e4ycyr2oq
26 Jul 22
Key financial highlights and outlook
4:56pm
DEFA14A
09rvz2opp5fwaij
13 Apr 22
Additional proxy soliciting materials
9:04am